the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

α-thalassemia

Interventions

BIOLOGICAL

α-globin restored autologous hematopoietic stem cells

α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C

Trial Locations (1)

RECRUITING

PLA Joint Logistic Support Force No. 923 Hospital, Nanning

All Listed Sponsors

lead

Shenzhen Hemogen

INDUSTRY